MENLO PARK, Calif. – Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, today announced the appointments of Bruce Wu, JD, PhD, as Chief Legal Officer and Dan Douglas as Vice President of Finance. Together, these life science veterans bring Deepcell new functional capabilities to help the organization scale to support an international commercial footprint and long-term growth.
“With Deepcell’s recent launch of our pioneering REM-I platform, we are poised to deliver on our founding purpose: leveraging cellular imaging and artificial intelligence to unlock insights from cell morphology, unlocking morpholomics, an entirely new ‘omics category,” said Maddison Masaeli, PhD, CEO of Deepcell. “Bruce and Dan are critical leaders who will help underpin our ability to innovate, sell, supply, and support our product portfolio and customers worldwide.”
As Chief Legal Officer, Bruce Wu, JD, PhD, is responsible for leading the legal function including corporate and intellectual property legal matters. Prior to joining Deepcell, he held senior legal executive leadership roles with General Inception, Sestina Bio, and Nutcracker Therapeutics. He previously held intellectual property-focused legal roles with Illumina and HP, Inc., and practiced as an intellectual property attorney at Foley & Lardner and Pillsbury Winthrop Shaw Pittman. Bruce Wu received his JD from Georgetown University, MS and PhD both in engineering from Massachusetts Institute of Technology, and BASc in engineering from the University of Toronto.
“Deepcell has built a remarkable technology platform which offers researchers a step-change in research capabilities,” said Bruce Wu. “Driving legal excellence, fostering a culture of compliance and making sure that Deepcell continues to build a strong IP portfolio, so that it can continue to support its customers with new products will remain my top priorities.”
As Vice President of Finance, Dan Douglas is responsible for leading the finance and accounting functions, as well as establishing and managing the financial and accounting systems necessary to support Deepcell’s growth and maturation. Prior to joining Deepcell, he held finance leadership roles at Slingshot Biosciences and Guardant Health as well as financial analysis roles with HotChalk, CenturyLink, and the General Services Administration. Dan Douglas received his MBA from the University of Denver and BA from Palm Beach Atlantic University.
“Organizations launching commercial products for the first time have unique challenges as they experience rapid growth and change,” said Dan Douglas. “My team will build the infrastructure to sustain Deepcell’s long-term growth,development and financial value creation.”
About Deepcell
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.
Media Contact
Gwen Gordon
Gwen@gwengordonpr.com
